8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 30, 2021

ALIMERA SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-34703		20-0028718
(State or other Jurisdiction of Incorporation)	(Commission File Number)		(IRS Employer Identification No.)
6120 Windward Parkway Suite 290 Alpharetta, Georgia		30005
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (678) 990-5740

Not Applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	ALIM	The Nasdaq Stock Market LLC (Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On December 1, 2021, Alimera Sciences, Inc. (the “Company”) issued a press release announcing that, based upon the recommendation of the Nominating and Corporate Governance Committee of the Company’s Board of Directors (the “Board”), on November 30, 2021 the Board appointed Erin Parsons to the Board as a Class III director, to serve until the Company’s annual meeting of stockholders in 2022. Ms. Parsons filled a vacancy on the Board created by the Board to permit her appointment. Ms. Parsons also was appointed to serve on the compensation committee of the Board (the “Compensation Committee”).

For more than 20 years, Ms. Parsons has focused on the ophthalmic industry, particularly in retina-related matters, overseeing scientific and medical communications, advocacy development and educational programs. Through her company, Parsons Medical Communications, she focuses solely on eyecare and provides several services in support of medical and scientific communications, including advocacy development, scientific platform/message creation and refinement, data dissemination/publication planning, market research and landscape assessments, and various other support services.

In connection with her election to the Board and pursuant to the Company’s non-employee director compensation program (as recently amended, the “Director Compensation Program”), the Compensation Committee granted to Ms. Parsons options to purchase 3,255 shares of the Company’s common stock at an exercise price of $5.23, the closing price per share of the common stock on November 30, 2021, the date on which she joined the Board. The options will vest and become exercisable in equal monthly installments of 465 shares on the 15th day of each month from December 15, 2021 through June 15, 2022, provided Ms. Parsons provides continuous service to the Company through the applicable vesting date. In the event of a change of control of the Company or if Ms. Parsons’s service terminates due to her death or disability, the options will accelerate and immediately become exercisable. Also pursuant to the Director Compensation Program, Ms. Parsons will receive a $40,000 annual retainer for her service on the Board and a $7,000 annual retainer for her service on the Compensation Committee, in each case prorated to the 2022 annual meeting of stockholders. In addition, under the Director Compensation Program she will be eligible to receive, upon the conclusion of each annual meeting of stockholders beginning in 2022, options to purchase an additional 6,000 shares of the Company’s common stock, provided she is then continuing to serve on the Board.

Ms. Parsons and the Company will also enter into an indemnification agreement requiring the Company to indemnify her to the fullest extent permitted under Delaware law with respect to her service as a director. The indemnification agreement will be in the form the Company has entered into with its other directors and executive officers. This form is filed as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 (SEC File No. 333-162782), as filed with the SEC on October 30, 2009.

There are no arrangements or understandings between Ms. Parsons and any other person pursuant to which she was appointed as a director. There are no transactions in which Ms. Parsons has or will have an interest that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

Item 7.01. Regulation FD Disclosure

On December 1, 2021, the Company issued a press release announcing the appointment of Ms. Parsons to the Board. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

‎

2

Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits

Exhibit No.	Description
99.1	Press Release of Alimera Sciences, Inc. dated December 1, 2021
104	Cover Page Interactive Data File (embedded within the inline XBRL document)

‎

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ALIMERA SCIENCES, INC.
Dated: December 1, 2021	By:	/s/ J. Philip Jones
	Name:	J. Philip Jones
	Title:	Chief Financial Officer

4

EX-99.1

Exhibit 99.1

Alimera SciencesWelcomes Ophthalmic Strategic Consultant

Erin Parsons to Its Board of Directors

ATLANTA  (December1, 2021) –  Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer,  today announces the addition of Erin Parsons to its Board of Directors. Ms.Parsons has more than 20 years of experience working in the ophthalmic industryoverseeing scientific strategy,medical communications, advocacy development, and peer-to-peer educational programs, much of this in the retina space.

“Erin’s extensiveophthalmic expertise and retinabackgroundwill bring additionalperspectives toour strategic initiatives to increase ILUVIEN advocacy and our engagement with the physician community as we strive to make Alimera the place to be in retina,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer.  “We look forward to benefitting from her professional relationships, deep industry knowledge, and significant clinical understanding.”

“I amexcited to join Alimera’s Board of Directors and contribute to a company and a brand that provide innovative long-term solutions toretinal physicians and their patients.I look forward to working closely with Alimera to ensure the benefits of ILUVIEN are well-understood and it is positioned to be a foundational treatment for retinal disease,” added Ms. Parsons.

Erin Parsons is a respected and highly sought-after ophthalmic industry veteran based in Boston, MA. She has wide-ranging experience in several therapeutic areas in eyecare including nearly every major disease state of the eye. Over a decade ago, she founded the eyecare-only medical strategy and communications company,Parsons Medical Communications (PMC). She was involved in the launch of LUCENTIS® (Roche/Genentech) and has experience with other retina products and programs includingpegcetacoplan, an investigational therapy for geographic atrophy (Apellis);  OTT166, an investigational topical integrin inhibitor for diabetic retinopathy (OcuTerra);Encapsulated Cell Therapy for retina disease(Neurotech); ForeseeHome® monitoring

device (Notal Vision); antisense oligonucleotide gene therapy (Wave Therapeutics);  and BEOVU® and TRIESENCE® for retinal disease (Novartis).

As a trusted collaborator with executives at top ophthalmic companies, Ms. Parsonsconsistently brings actionable development plans and commercial insights to stakeholders inside and outside of the eyecare community.Sheis also involved with various associations in the eyecare space including Ophthalmic World Leaders (OWL), the Ophthalmology Innovation Summit (where she led a Masterclass on KOL Advocacy), and The Holland Foundation for Sight Restoration.  

Ms. Parsons received a BS in Biology from Wake Forest University.

About Alimera Sciences, Inc.

Alimera Sciences a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.

For press inquiries:For investor inquiries:

Jules AbrahamScott Gordon

for Alimera Sciences for Alimera Sciences

917-885-7378scottg@coreir.com

julesa@coreir.com

#  #  #

XML

Document and Entity Information	Nov. 30, 2021
Document and Entity Information [Abstract]
Document Type	8-K
Document Period End Date	Nov. 30, 2021
Entity Registrant Name	ALIMERA SCIENCES, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-34703
Entity Tax Identification Number	20-0028718
Entity Address, Address Line One	6120 Windward Parkway
Entity Address, Address Line Two	Suite 290
Entity Address, City or Town	Alpharetta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30005
City Area Code	678
Local Phone Number	990-5740
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	ALIM
Security Exchange Name	NASDAQ
Emerging Growth Company	false
Entity Central Index Key	0001267602
Amendment Flag	false